Percutaneous Pulmonary Valve Implantation
- Author:
Luca GIUGNO
1
;
Alessia FACCINI
;
Mario CARMINATI
Author Information
- Publication Type:Review
- Keywords: Percutaneous pulmonary valve implantation; Transcatheter procedure; Congenital heart disease
- MeSH: Freedom; Heart Defects, Congenital; Humans; Incidence; Mortality; Prostheses and Implants; Pulmonary Valve; Venus
- From:Korean Circulation Journal 2020;50(4):302-316
- CountryRepublic of Korea
- Language:English
- Abstract: Percutaneous pulmonary valve implantation (PPVI) is recognized as a feasible and low risk alternative to surgery to treat dysfunctional right ventricular outflow tract (RVOT) in usually pluri-operated patients. Evolving technology allowed to develop different kind of prosthesis and to go from an initial treatment exclusively of stenotic conduit to an actual approach extended also to wide native RVOT. The Melody transcatheter pulmonary valve (TPV) and the Edwards Sapien valve are nowadays the most commonly implanted prostheses. However, other devices have been developed to treat large RVOT (i.e., the Venus p-valve, the Medtronic Harmony TPV, the Alterra Adaptive Prestent, and the Pulsta valve). Indications for PPVI are the same as for surgical interventions on pulmonary valve, with limits related to the maximum diameter of the available percutaneous prosthesis. Therefore, an accurate preoperative evaluation is of paramount importance to select patients who could benefit from this procedure. The overall periprocedural mortality incidence is around 1.4%, while freedom from RVOT reintervention ranges from 100% at 4 months to 70% at 70 months, according to the different published studies.
